Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: HRS9531, KAI-9531
Ribupatide is an investigational dual GLP-1/GIP receptor agonist developed for research in obesity and type 2 diabetes. Preclinical studies reported activity at both receptor pathways, subcutaneous bioavailability in animal models, and reductions in body weight and food intake in diet-induced obese mice. First-in-human evaluation reported subcutaneous administration, pharmacokinetic properties compatible with once-weekly dosing, and a mean half-life of approximately 7–8 days in the multiple-ascending-dose study.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence-backed study regimens: the first-in-human study evaluated single subcutaneous doses of 0.1, 0.3, 0.9, 2.7, 5.4, and 8.1 mg, and multiple subcutaneous dosing of 0.9, 2.7, and 5.4 mg once weekly for 4 weeks, including a 2.7/2.7/4.0/5.4 mg escalation sequence. A 2026 American Diabetes Association conference abstract reported oral ribupatide doses of 10, 25, or 50 mg for 26 weeks in adults with obesity without diabetes. These are clinical-study regimens and not prescribing or self-administration guidance. Ribupatide remains an investigational compound in the cited records.
Supplementary research context only. Not medical advice or a treatment recommendation.
International Nonproprietary Name (INN): ribupatide; development codes: HRS9531 and KAI-9531; ClinicalTrials.gov identifier for first-in-human study: NCT05152277; DOI: 10.1111/dom.71218
Ribupatide is a chemically synthesized peptide/polypeptide. The WHO proposed INN publication provides a peptide chemical description. Public clinical research records identify both injectable and oral development programs. No common commercial or catalog reference size was established from authoritative scientific sources.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Ribupatide or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.